SuperworthSpruce Biosciences price to sales ratio SPRB
Market value divided by revenue over the last twelve months, since 2024.
- Today, Oct 23, 2026
- n/m
- not a meaningful number
- Last meaningful
- 85.8×
- Mar 2026
- Peer median
- 1.4×
Spruce Biosciences' price to sales ratio is not a meaningful number today: revenue for one or more of the four quarters through 2026-06-30 is missing, so twelve months can't be added up.
It was last meaningful in Mar 2026, at 85.8×.
Price to sales ratio over time
Year by year
| Year | End of year | Low | High |
|---|---|---|---|
| 2026 so far | 85.8× | 76.4× | 139× |
| 2025 | 132× | 0.6× | 163× |
| 2024 | 2.5× | 1.8× | 3.4× |
Against its peers
Companies in Drug Manufacturers - General nearest Spruce Biosciences' size, closest first, today.
| Company | Price to sales ratio |
|---|---|
| SPRBSpruce Biosciences | n/m |
| NATRNatures Sunshine Products | 0.4× |
| LFVNLifevantage | 0.4× |
| SPROSpero Therapeutics | 1.4× |
| ATNMActinium Pharmaceuticals | n/m |
| ARVNArvinas | 1.5× |
| PBYIPuma Biotechnology | 2.5× |
| IRWDIronwood Pharmaceuticals | 1.5× |
| ZVRAZevra Therapeutics | 4.3× |
| CRMDCorMedix | 1.3× |
| COLLCollegium Pharmaceutical | 0.9× |
| Peer median | 1.4× |
What the price to sales ratio tells you
Market value divided by revenue over the last twelve months. Useful for companies with little or no profit yet, since sales are harder to make negative than earnings.
Ignores margins entirely. A software company at 10× sales with 30% margins can be cheaper than a grocer at 1× sales with 2% margins.
More on Spruce Biosciences
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.